PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients

OBJECTIVES: The objective of this study is to evaluate whether PIV (Pan-Immune-Inflammation Value) and PILE [a score derived from PIV, lactate dehydrogenase (LDH), and Eastern Cooperative Oncology Group Performance Status (ECOG PS)] can predict clinical outcome of anti-PD-1/PD-L1 inhibitor combined...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Ran, Liu, Fang, Fang, Chen, Yang, Jin, Luo, Lifeng, Yue, Ping, Gao, Beili, Dong, Yuchao, Xiang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586214/
https://www.ncbi.nlm.nih.gov/pubmed/34777341
http://dx.doi.org/10.3389/fimmu.2021.724443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586214/
https://www.ncbi.nlm.nih.gov/pubmed/34777341
http://dx.doi.org/10.3389/fimmu.2021.724443

Ejemplares similares